JP2008546751A - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP2008546751A
JP2008546751A JP2008517587A JP2008517587A JP2008546751A JP 2008546751 A JP2008546751 A JP 2008546751A JP 2008517587 A JP2008517587 A JP 2008517587A JP 2008517587 A JP2008517587 A JP 2008517587A JP 2008546751 A JP2008546751 A JP 2008546751A
Authority
JP
Japan
Prior art keywords
phenyl
pyrazol
group
compound
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008517587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546751A5 (enExample
Inventor
トーマス・グランモア・デイビス
ロバート・ジョージ・ボイル
イアン・コリンズ
ミシェル・ドーン・ガレット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital, Cancer Research Technology Ltd, Astex Therapeutics Ltd filed Critical Institute of Cancer Research Royal Cancer Hospital
Publication of JP2008546751A publication Critical patent/JP2008546751A/ja
Publication of JP2008546751A5 publication Critical patent/JP2008546751A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
JP2008517587A 2005-06-22 2006-06-21 医薬組成物 Pending JP2008546751A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69300205P 2005-06-22 2005-06-22
US69296105P 2005-06-22 2005-06-22
PCT/GB2006/002276 WO2006136821A1 (en) 2005-06-22 2006-06-21 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
JP2008546751A true JP2008546751A (ja) 2008-12-25
JP2008546751A5 JP2008546751A5 (enExample) 2009-08-06

Family

ID=37027831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008517587A Pending JP2008546751A (ja) 2005-06-22 2006-06-21 医薬組成物

Country Status (4)

Country Link
US (1) US8343953B2 (enExample)
EP (1) EP1902032A1 (enExample)
JP (1) JP2008546751A (enExample)
WO (1) WO2006136821A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526547A (ja) * 2017-07-12 2020-08-31 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 心不全の治療のためのｒｏｃｋの５員アミノヘテロ環および５，６−または６，６員二環式アミノヘテロ環の阻害剤

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004303602C1 (en) 2003-12-23 2009-05-28 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
WO2009025957A1 (en) * 2007-08-22 2009-02-26 Takeda Pharmaceuticals Company Limited Erythropoietin receptor peptide formulations and uses
JP2008546751A (ja) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
US8541461B2 (en) 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
GB0704932D0 (en) * 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
WO2009005460A1 (en) * 2007-06-29 2009-01-08 Astrazeneca Ab Small molecule inhibitors of navl.7 sodium channels for the treatment of pain disorders
BRPI0821773B8 (pt) * 2007-12-27 2021-05-25 Kissei Pharmaceutical monossebacato cristalino de bis[3-(3-{4-[3-(beta-dglicopiranosilóxi)-5-isopropil-1h-pirazol-4-ilmetil]-3-metilfenóxi}propilamino)-2,2-dimetil-propionamida], composição farmacêutica e medicamento compreendendo o dito composto
US20170157038A1 (en) * 2008-11-13 2017-06-08 Gholam A. Peyman Ophthalmic drug delivery method
KR101699991B1 (ko) 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
EA020302B1 (ru) 2009-08-07 2014-10-30 Мерк Патент Гмбх Новые азагетероциклические соединения
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
ES2729754T3 (es) 2010-07-29 2019-11-06 Merck Patent Gmbh Carboxamidas azaheterocíclicas de aminas cíclicas
SI2643313T1 (sl) 2010-11-24 2016-11-30 Merck Patent Gmbh Kinazolin-karboksamidni azetidini
LT2755965T (lt) 2011-09-12 2017-11-10 Merck Patent Gmbh Naujieji imidazolo aminai kaip kinazės aktyvumo moduliatoriai
KR101992505B1 (ko) 2011-09-12 2019-06-24 메르크 파텐트 게엠베하 키나아제 활성의 조절제로서 용도를 위한 아미노피리미딘 유도체
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US9139568B2 (en) 2011-12-22 2015-09-22 Merck Patent Gmbh Heterocyclic carboxamides as modulators of kinase activity
CN110078743A (zh) 2012-11-16 2019-08-02 默克专利有限公司 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
MX2015006516A (es) 2012-11-29 2015-08-14 Merck Patent Gmbh Derivados de azaquinolin-carboxamida.
EP2970201B1 (en) 2013-03-11 2019-06-19 Merck Patent GmbH 6-[4-(1h-imidazol-2-yl)piperidin-1-yl]pyrimidin-4-amine derivatives as modulators of kinase activity
US9980966B2 (en) 2014-04-03 2018-05-29 Merck Patent Gmbh Combinations of cancer therapeutics
KR20230110296A (ko) 2020-11-16 2023-07-21 메르크 파텐트 게엠베하 암 치료를 위한 키나제 억제제 조합

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000016984A (ja) * 1998-03-05 2000-01-18 Pfizer Inc デルタオピオイドアゴニストとしての化合物
JP2007516272A (ja) * 2003-12-23 2007-06-21 アステックス、セラピューティックス、リミテッド タンパク質キナーゼモジュレーターとしてのピラゾール誘導体

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0457803A4 (en) 1989-02-08 1991-12-04 Abbott Laboratories 4-hydroxythiazoles as 5-lipoxygenase inhibitors
US5049570A (en) 1990-01-23 1991-09-17 Du Pont Merck Pharmaceutical Company Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5532356A (en) * 1995-06-06 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N,N'-disubstituted cyclic ureas
GB9512961D0 (en) * 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
CA2249645A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB2339298B (en) * 1996-04-30 2000-05-10 Eastman Kodak Co Use of pyrazolone image dye-forming couplers for enhancing light stability
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
GB9700555D0 (en) * 1997-01-13 1997-03-05 Merck Sharp & Dohme Therapeutic agents
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
WO1999038508A1 (en) 1998-01-29 1999-08-05 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
US6503905B1 (en) 1998-12-29 2003-01-07 Pfizer Inc 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
WO2000066562A1 (en) 1999-05-03 2000-11-09 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
AU767440B2 (en) 1999-05-14 2003-11-13 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo(1,2-A)pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
WO2001019798A2 (en) 1999-09-17 2001-03-22 Cor Therapeutics Inc. INHIBITORS OF FACTOR Xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EP1216228B1 (en) 1999-09-17 2008-10-29 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
IL152807A0 (en) 2000-05-30 2003-06-24 Peptor Ltd Protein kinase inhibitors
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
WO2002088090A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
CA2456192A1 (en) 2001-08-03 2003-02-13 Qing Tang Pyrazole-derived kinase inhibitors and uses thereof
FR2830192B1 (fr) 2001-09-28 2004-08-20 Oreal Composition tinctoriale comprenant une base d'oxydation du type diaminopyrazole et un coupleur pyrazolo-azole
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
MXPA04007470A (es) 2002-02-14 2004-11-10 Pharmacia Corp Piridinonas sustituidas.
CA2479338A1 (en) 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
AU2003213058A1 (en) 2002-04-08 2003-10-27 Barosense, Inc. Satiation devices and methods
WO2003090680A2 (en) 2002-04-23 2003-11-06 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
ES2385378T3 (es) 2002-07-24 2012-07-24 Dermira (Canada), Inc. Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos
AU2003299045A1 (en) * 2002-09-18 2004-04-08 The Curators Of The University Of Missouri OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR
CN100546657C (zh) * 2002-11-21 2009-10-07 贝希尔治疗学股份有限公司 预防和治疗疾病的方法及免疫调节核酸组合物
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
EP1644365A2 (en) 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
EP1679308B1 (en) * 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
US20050171171A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as FLT-3 modulators
US7439254B2 (en) 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
WO2006071819A1 (en) 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
GB2427406A (en) 2005-06-21 2006-12-27 Astex Technology Ltd Silicon-containing PKB/PKA kinase inhibitors
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
AR054485A1 (es) 2005-06-21 2007-06-27 Cancer Rec Tech Ltd ARIL-ALQUILAMINAS Y HETEROARIL-ALQUILAMINAS COMO INHIBIDORES DE PROTEINA QUINASA A Y B, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ORIGINADAS EN EL CRECIMIENTO ANORMAL DE LA
JP2008543919A (ja) 2005-06-21 2008-12-04 アステックス・セラピューティクス・リミテッド 医薬化合物
JP2008546751A (ja) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
US8541461B2 (en) 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000016984A (ja) * 1998-03-05 2000-01-18 Pfizer Inc デルタオピオイドアゴニストとしての化合物
JP2007516272A (ja) * 2003-12-23 2007-06-21 アステックス、セラピューティックス、リミテッド タンパク質キナーゼモジュレーターとしてのピラゾール誘導体
JP4928949B2 (ja) * 2003-12-23 2012-05-09 アステックス、セラピューティックス、リミテッド タンパク質キナーゼモジュレーターとしてのピラゾール誘導体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526547A (ja) * 2017-07-12 2020-08-31 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 心不全の治療のためのｒｏｃｋの５員アミノヘテロ環および５，６−または６，６員二環式アミノヘテロ環の阻害剤
JP7234201B2 (ja) 2017-07-12 2023-03-07 ブリストル－マイヤーズ スクイブ カンパニー 心不全の治療のためのｒｏｃｋの５員アミノヘテロ環および５，６－または６，６員二環式アミノヘテロ環の阻害剤

Also Published As

Publication number Publication date
US20100130464A1 (en) 2010-05-27
US8343953B2 (en) 2013-01-01
EP1902032A1 (en) 2008-03-26
WO2006136821A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
KR101164258B1 (ko) 단백질 키나아제 조절제로서의 피라졸 유도체
JP2008546751A (ja) 医薬組成物
JP5606734B2 (ja) 医薬化合物
US20090253718A1 (en) Pharmaceutical Compounds
US20100210617A1 (en) Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors
JP2009534454A (ja) 医薬化合物
JP2010526800A (ja) オキサゾールチロシンキナーゼ阻害剤
WO2006136823A1 (en) Heterocyclic containing amines as kinase b inhibitors
JP2008543919A (ja) 医薬化合物
CN1922148B (zh) 作为蛋白激酶调节剂的吡唑衍生物
US20240182461A1 (en) Selective angiotensin ii receptor ligands
CN101479263A (zh) 药用化合物
ES2354162T3 (es) Derivados de pirazol como modulares de proteína quinasas.
HK1097543B (en) Pyrazole derivatives as protein kinase modulators
SA05260179B1 (ar) مركبات اريل الكيل امين واريل غير متجانس الكيل امين تحتوي على بيرازول تثبط أو تعدل من نشاط الكيناز البروتيني a (pks) والكيناز البروتيني b (pkb)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20120605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120824

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121002

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121030

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130514